Unfortunately, the original version of this article \[[@CR1]\] contained errors. There were formatting errors in the main text and in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}. These tables have been included correctly below. There will also be an update to correct the errors in the main text.Table 1Cost data sourcesItemCost sourcesDrugsGerman Rote Liste 2013, web-based researchAmbulatory medical treatmentGerman value measurement (EBM 2000+) and fee regulations for doctors (GOÄ)Non-pharmacological therapiesAccording to agreements between German health insurance funds and professional organizationsMedical devices / aidsWeb-based researchHospitalisation and RehabilitationGerman Diagnosis-Related Groups (G-DRG), web- and phone-based researchNursing home careAccording to German long term care insuranceReduction in earning capacityAverage payments according to German retirement insuranceTable 2Patient demography and other baseline characteristicsINCO pretreated\
*N* = 67INCO naïve\
*N* = 41INCO total\
*N* = 108CON *N* = 110Total *N* = 218Gender (m)36 (53.7 %)22 (53.7 %)58 (53.7 %)70 (63.6 %)128 (58.7 %)Age (years)62.3 (10.7)60.7 (16.0)61.7 (12.9)67.8 (12.7)64.8 (13.1)Body mass index (kg/m^2^)26.7 (4.0)26.8 (4.4)26.7 (4.1)27.7 (4.8)27.2 (4.5)Time since apoplex (years)8.0 (5.6)6.8 (6.1)7.5 (5.8)5.3 (5.1)6.5 (5.6)Time since spasticity (years)6.9 (6.3)6.0 (6.5)6.6 (6.3)4.9 (5.4)5.7 (5.9)Concomitant diseases (yes)55 (82.1 %)29 (70.7 %)84 (77.8 %)96 (87.3 %)180 (8.6 %)Employed (yes)1 (1.5 %)3 (7.3 %)4 (3.7 %)9 (8.2 %)13 (6.0 %)Retired (yes)58 (96.7 %)39 (97.5 %)87 (94.6 %)86 (86.9 %)173 (90.6 %)Early retirement due to spasticity (yes)40 (63.5 %)20 (55.6 %)60 (60.6 %)19 (20.4 %)79 (41.1 %)Reduction in earning capacity due to spasticity (yes)22 (32.9 %)11 (26.8 %)33 (30.6 %)23 (20.9 %)56 (25.7 %)Level of care (none)12 (17.9 %)10 (24.4 %)22 (20.4 %)37 (35.6 %)59 (27.8 %)Level 128 (41.8 %)15 (36.6 %)43 (39.8 %)33 (31.7 %)76 (35.8 %)Level 223 (34.3 %)15 (36.6 %)38 (35.2 %)29 (27.9 %)67 (31.6 %)Level 34 (6.0 %)1 (2.4 %)5 (4.6 %)5 (4.8 %)10 (4.7 %)All values are means (± standard deviation) or number of patients (%)Table 3Overview of antispastic therapies and measures during the studyIncobotulinumtoxinA group:\
Antispastic medications except BoNT/A, non-pharmacological therapies and aidsFirst quarter (n = 108)Second quarter (n = 102)Third quarter (n = 99)Fourth quarter (n = 94)Oral medication31 (28.7 %)23 (32.4 %)20 (20.2 %)18 (19.1 %)Physical therapy60 (55.6 %)54 (52.9 %)54 (54.5 %)51 (54.3 %)Occupational therapy43 (39.8 %)42 (41.2 %)41 (41.4 %)44 (46.8 %)Speech therapy10 (9.3 %)8 (7.8 %)8 (8.1 %)9 (8.6 %)Other therapies3 (2.8 %)6 (6.0 %)4 (4.0 %)4 (4.3 %)Therapeutic aids12 (11.0 %)5 (5.7 %)-1 (1.0 %)Conventional therapy group:\
Antispastic medications, non-pharmacological therapies and aidsFirst quarter (n = 110)Second quarter (n = 98)Third quarter (n = 91)Fourth quarter (n = 84)Oral medication67 (60.9 %)66 (67.3 %)63 (69.2 %)58 (69.0 %)Physical therapy68 (61.8 %)59 (60.2 %)54 (54.5 %)52 (61.9 %)Occupational therapy15 (13.6 %)11 (11.2 %)11 (12.1 %)8 (9.5 %)Speech therapy5 (4.6 %)5 (5.1 %)5 (5.5 %)4 (4.8 %)Other therapies3 (2.7 %)5 (5.1 %)-1 (1.2 %)Therapeutic aids10 (11.0 %)8 (8.2 %)12 (13.2 %)8 (9.5 %)Table 4Responder analyses at study end after 1-year of treatmentINCO pretreatedINCO naïveINCO totalCONINCO pretr. vs. CONINCO naïve vs. CONINCO total vs. CONShoulder adduction/internal rotation56.473.962.915.5\<0.01\<0.01\<0.01Shoulder abduction65.510073.019.7\<0.01\<0.01\<0.01Shoulder elevation66.788.972.720.6\<0.01\<0.01\<0.01Flexed elbow78.392.983.826.9\<0.01\<0.01\<0.01Forearm pronation81.473.779.022.0\<0.01\<0.01\<0.01Flexed wrist82.194.786.226.6\<0.01\<0.01\<0.01Thumb-in-palm77.881.378.820.0\<0.01\<0.01\<0.01Clenched fist79.195.284.422.2\<0.01\<0.01\<0.01Intrinsic-plus-position of the hand73.310078.919.5\<0.01\<0.01\<0.01Responder rates (%); response was definded as ≥ 1-point improvement on the Ashworth Scale for all treated muscle groups at study end; Fisher´s exact test was used for group comparisonsTable 5Overview of total costs by cost centers (in €)INCO *n* = 93CON *n* = 83Ambulatory medical treatment175217Drugs3,386193Hospitalizations (including rehabilitation measures)40138Non-pharmacological therapies1,408998Medical devices / aids7912Nursing home care3,0892,203Total direct costs8,1883,806Reduction in earning capacity2,081988Total costs10,2684,794Table 6Overview of Cost-utility ratios and ICERUtility parameterINCOCON*Responder rate in Ashworth Score per clinical patternResponder rateCost-utility ratioResponder rateCost-utility ratioICER*Shoulder adduction / internal rotation62.9 %16,325 €15.5 %30,929 €11,549 €Shoulder abduction73.0 %14,066 €19.7 %24,335 €10,271 €Shoulder elevation72.7 %14,124 €20.6 %23,272 €10,507 €Flexed elbow83.8 %12,253 €26.9 %17,821 €9,621 €Pronated forearm79.0 %12,998 €22.0 %21,791 €9,604 €Flexed wrist86.2 %11,912 €26.6 %18,022 €9,185 €Thumb-in-palm78.8 %13,031 €20.0 %23,970 €9,310 €Clenched fist84.4 %12,166 €22.2 %21,595 €8,801 €Intrinsic-Plus-position (hand)78.9 %13,014 €19.5 %24,585 €9,216 €*Improvement in SF-12 dimensionImprovementCost-utility ratioImprovementCost-utility ratioICER*Physical Health7.961,290 €0.835,776 €768 €Mental Health10.75955 €5.71840 €1,086 €Incremental Cost-Effectiveness Ratio (ICER) = (Total costs INCO -- Total costs CON)/(Utility value INCO -- Utility value CON)

The online version of the original article can be found under doi:10.1186/s13561-016-0107-5.
